Zenas BioPharma
ZBIO
28.18
+1.24
+4.60%
Zenas BioPharma
US · ZBIO
#2856 by market cap
Listed 2024
28.18
+1.24
+4.60%
Live - 5344 symbols - heartbeat 506s ago
· 2026-10-08 07:09
Pre-market
28.26
+0.28%
After-hours
28.18
0.00%
- Market cap
- 1.84B
- P/E (TTM)i
- -2.93
- P/Bi
- 7.43
- EPSi
- -8.44
- Div yieldi
- 0.00%
- 52W posi
- 47%
Reader sentiment
Are you bullish or bearish on ZBIO?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 5 analysts
Buy
Avg price target
44.80 +59.0%
Price target rangecurrent 28.18
Low32.00
Avg44.80
High55.00
Buy 80%
Hold 20%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | Citi | -- | BUY | 48.00 |
| 2026-09-30 | Wedbush | -- | BUY | 45.00 |
| 2026-09-30 | Citi | -- | BUY | 48.00 |
| 2026-09-30 | H.C. Wainwright | -- | BUY | 44.00 |
| 2026-09-21 | H.C. Wainwright | -- | BUY | 44.00 |
| 2026-09-10 | Citi | -- | BUY | 41.00 |
| 2026-08-17 | Morgan Stanley | -- | HOLD | 32.00 |
| 2026-08-14 | H.C. Wainwright | -- | BUY | 44.00 |
| 2026-08-13 | Guggenheim | -- | BUY | 55.00 |
| 2026-06-25 | H.C. Wainwright | -- | BUY | 44.00 |
| 2026-06-08 | H.C. Wainwright | -- | BUY | 44.00 |
| 2026-06-05 | Guggenheim | -- | BUY | 55.00 |
| 2026-05-14 | Wedbush | -- | BUY | 45.00 |
| 2026-05-14 | Morgan Stanley | -- | HOLD | 22.00 |
| 2026-05-13 | Citi | -- | BUY | 41.00 |
| 2026-03-17 | Evercore | -- | BUY | 55.00 |
| 2026-03-17 | Citi | -- | BUY | 41.00 |
| 2026-03-16 | Guggenheim | -- | BUY | 55.00 |
| 2026-02-12 | Evercore | -- | BUY | 55.00 |
| 2026-02-10 | H.C. Wainwright | -- | BUY | 44.00 |
| 2026-01-30 | Citi | -- | BUY | 43.00 |
| 2026-01-12 | Evercore | -- | BUY | 55.00 |
| 2026-01-11 | Citi | -- | BUY | 43.00 |
| 2026-01-06 | Morgan Stanley | -- | HOLD | 19.00 |
| 2026-01-06 | Evercore | -- | BUY | 55.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Hold
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Morgan Stanley moved from Buy to Hold on 2026-01-06.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-01-06 | Morgan Stanley | BUY → HOLD | 19.00 |
Quote time 2026-10-08 07:09:11 · For reference only, not investment advice and not tailored to your situation.